Quantcast
Last updated on April 18, 2014 at 6:03 EDT

Latest Exosome Stories

2013-10-24 08:36:23

SAN DIEGO, Oct. 24, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) (Logo: http://photos.prnewswire.com/prnh/20130912/LA78266LOGO) Last week, the Wall Street Journal published an informative article on the emergence of cancer immunotherapies designed to augment the immune system's ability to recognize and combat malignant...

2013-10-15 08:31:57

SAN DIEGO, Oct. 15, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Logo: http://photos.prnewswire.com/prnh/20130912/LA78266LOGO) (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) In recent months, we launched and staffed a diagnostic subsidiary, expanded our intellectual property portfolio, and continued to generate revenues from established and newly awarded government...

2013-09-30 08:29:38

NEW YORK, Sept. 30, 2013 /PRNewswire/ -- Exosome Diagnostics today announced that it has selected Cedars-Sinai Medical Center to participate in an early technology access program for use of exosome RNA biofluid extraction kits for biomarker discovery in neo-natal and other disease settings. "The ability to monitor patients, particularly extreme premature infants, using real-time biofluid based genetics tests, may provide critical information which is currently unavailable, said...

2013-09-24 08:30:56

SAN DIEGO, Sept. 24, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Dr. Cicek Gercel-Taylor has been appointed Clinical Research Director of Exosome Sciences, Inc. (ESI), a wholly-owned diagnostic subsidiary of Aethlon Medical. In this role, Dr. Gercel-Taylor will direct and plan the execution of diagnostic clinical programs and interact with collaborative partners and regulatory authorities. (Logo:...

2013-09-19 08:28:42

NEW YORK, Sept. 19, 2013 /PRNewswire/ -- Exosome Diagnostics today announced it has entered into a collaboration agreement with Eli Lilly and Company (NYSE: LLY) for biomarker discovery and validation using Exosome Diagnostics proprietary EXO50 nucleic acid extraction kit. Under the agreement, Lilly will gain early access to Exosome Diagnostics technology to help identify key gene mutations and expression levels in blood that may be correlated with drug response and disease...

2013-09-13 08:23:26

SAN DIEGO, Sept. 13, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Dr. Douglas Taylor has accepted the position of Chief Scientific Officer at Exosome Sciences, Inc. (ESI), a wholly owned diagnostic subsidiary of Aethlon Medical. Dr. Taylor is credited with the discovery of tumor-secreted exosomes and is a leading published author on the topic. "We are truly honored that Dr. Taylor has agreed to lead our research endeavors at Exosome Sciences. His...

2013-09-12 08:31:12

SAN DIEGO, Sept. 12, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today announced the formal launch of Exosome Sciences, Inc. (ESI), a wholly-owned subsidiary previously established by Aethlon to pursue exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. Exosomes produced by diseased cells represent an optimal diagnostic target as they are shed into bodily fluids such as urine and blood...

2013-09-05 08:29:11

SAN DIEGO, Sept. 5, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Company Chairman and CEO, Jim Joyce has accepted an invitation to present at the Exosomes and Circulating Biomarkers 2013 Summit on September 12(th). Mr. Joyce's presentation is entitled; "Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer." The presentation will highlight the clinical advancement of the Aethlon...

2013-08-22 08:27:03

Cell biologists are excited by the medical potential of exosomes. A novel exosome purification technology, released today by Cell Guidance Systems, is set to transform the field. CAMBRIDGE, England, Aug. 22, 2013 /PRNewswire/ -- Once thought to be just part of the cells waste disposal system, it is now clear that exosomes also act as microscopic delivery bags, protecting RNA and protein contents that can then be transported in the blood, influencing the activity of distant cells....

2013-08-21 23:21:31

Under the agreement, Mount Sinai will retain rights to molecular biomarkers associated with disease progression and drug response, and Exosome Diagnostics will retain commercial development rights for molecular in vitro diagnostic products. New York, NY (PRWEB) August 21, 2013 The Icahn School of Medicine at Mount Sinai and Exosome Diagnostics today announced a collaboration on the research and development of real-time nucleic acid-based body-fluid diagnostics to advance personalized...